Abstract

Statin Market was valued nearly US$ 16 Billion in 2023 and is expected to reach nearly US$ 19 Billion by 2030, at a CAGR of 3% during forecast. An increase in occurrence of centripetal obesity, cardiovascular diseases and diabetes among geriatric populations are expected to drive the demand for effective treatment of high cholesterol. On average more than 50% of old adult population suffers from modest to high LDL levels, leading to myocardial infarction and stroke in affected population. The current prevalence rate of stroke, over 55 years, varies from 45 to 150/ 100,000 population. Between 51-60 years, the incidence of myocardial infarction is 15 %. Statins on long term usage lead to cardiovascular protection not only by reducing the cholesterol levels but also by decreasing LDL-cholesterol oxidation and by promoting the stabilization of the atheroma plaque. Adults aged 40 to 75 years who have 1 or more cardiovascular risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD risk of 10% or greater require statin intervention. Statins have disadvantages of causing hyperglycemia and weight gain but their overall advantage of protection in terms of CV events is more effective. The basic use of statins is in hyperlipidemia and mixed dyslipidemia, where they are used in more than 50% cases.